Related Experiment Video

Updated: Nov 3, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

954

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Bulent Kantarcioglu1, Omer Iqbal1, Jeanine M Walenga1

  • 1Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|June 1, 2021
PubMed

Insights

Coronavirus disease 2019 (COVID-19) presents ongoing challenges, but safe and effective vaccines are key to ending the pandemic. This review examines COVID-19

Area of Science:

  • Infectious Diseases
  • Immunology
  • Vaccinology

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, remains a global health concern with many unresolved virological, pathophysiological, and immunological questions.
  • Despite advancements, understanding the full spectrum of COVID-19's impact, particularly its thrombotic features, is crucial.

Purpose of the Study:

  • To summarize the pathophysiological and thrombotic characteristics of COVID-19.
  • To review the safety and efficacy of approved COVID-19 vaccines.
  • To address recent concerns regarding thromboembolic events following COVID-19 vaccination.

Main Methods:

  • Literature review and data synthesis on COVID-19 pathogenesis.
  • Analysis of clinical trial data and post-marketing surveillance for vaccine safety and efficacy.
  • Assessment of reported thromboembolic events in vaccinated individuals.

Main Results:

  • COVID-19 is associated with significant pathophysiological changes, including thrombotic complications.
  • Approved COVID-19 vaccines demonstrate high safety and efficacy profiles.
  • Current evidence suggests that the benefits of vaccination outweigh the rare risks of thromboembolic events.

Conclusions:

  • Vaccination remains the most effective strategy to control the COVID-19 pandemic.
  • Ongoing monitoring and research are necessary to address emerging variants and vaccine-related concerns.
  • Objective assessment of data is vital for maintaining public trust and guiding vaccination strategies.

Keywords:
COVID-19SARS-CoV-2heparin induced thrombocytopeniasafety and efficacythrombocytopeniathrombosis

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.3K
Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots06:12

Author Spotlight: A Novel Method for Comprehensive Cell Component Analysis of Cerebral Blood Clots

Published on: July 21, 2023

775

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.5K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
99
Vaccinations01:51

Vaccinations

Overview
48.1K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
86
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K